High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.

BACKGROUND: BRAF V600E mutations are activating mutations that have recently been detected in ameloblastoma. However, their prevalence has not been reported in East Asian patients with ameloblastoma and their clinicopathological significance remains unclear. In this study, we examined the prevalence and clinicopathological significance of BRAF V600E mutations in Korean patients with ameloblastoma. In addition, we investigated the relationship between BRAF V600E mutations and epithelial-mesenchymal transition, which has not been studied in ameloblastoma. METHODS: Thirty ameloblastoma tissue samples were collected, and DNA isolation, polymerase chain reaction, and Sanger sequencing were performed to detect BRAF V600E mutations. Immunohistochemistry was carried out using antibodies against two epithelial-mesenchymal transition-inducing transcription factors, Twist and Snail. Associations of BRAF V600E mutations with clinicopathological factors and expression of Twist and Snail were statistically analyzed. RESULTS: We found a high frequency (90.0%) of BRAF V600E mutations, and mutation status was not associated with clinicopathological factors including age, tumor location, and recurrence. Positive expression of Twist and Snail was observed in 33.3% and 56.7% of cases, respectively, and associated with recurrence (P = 0.020 and 0.010, respectively). There was no correlation between BRAF V600E mutation status and expression of Twist and Snail (P = 1.000, for both). CONCLUSIONS: A higher prevalence of BRAF V600E mutations was identified in Korean patients with ameloblastoma compared with previous studies, which indicates that BRAF-targeted therapies can be widely used for refractory ameloblastomas. Furthermore, our findings suggest that BRAF V600E mutations and epithelial-mesenchymal transition may act independently in the development of ameloblastoma.

Twist and Snail expression in tumor and stromal cells of epithelial odontogenic tumors.

BACKGROUND: The aims of this study were to evaluate expression of Twist and Snail in tumor and stromal cells of epithelial odontogenic tumors and to analyze relationships between Twist and Snail expression and between tumor and stromal expression. METHODS: Immunohistochemistry was performed using Twist and Snail antibodies in 60 ameloblastomas (AMs; 20 solid/multicystic, 20 unicystic, and 20 recurrent), six ameloblastic carcinomas (ACs), 10 adenomatoid odontogenic tumors (AOTs), and six calcifying epithelial odontogenic tumors (CEOTs). RESULTS: A higher rate of tumor cells strongly positive for Twist was observed in AC compared to the other tumors (P = 0.019). The rate of tumor cells strongly positive for Snail tended to be higher in AC than in AM (P = 0.060). AM and AC showed a higher rate of Twist-positive stromal cells than AOT and CEOT (P < 0.001). Tumor cells of recurrent AM showed stronger expression of Twist (P < 0.001) and Snail (P = 0.001) compared to AM without recurrence. A moderate positive correlation was observed between tumor expression of Twist and Snail (r = 0.376, P = 0.001) and between tumor and stromal expression of Snail (r = 0.334, P = 0.002). CONCLUSIONS: Twist and Snail may affect the epithelial-mesenchymal transition in AC and be involved in recurrence of AM. Stromal Twist expression may be associated with aggressive clinical behavior of epithelial odontogenic tumors. A Twist-Snail pathway may participate in the development and progression of odontogenic tumors, and tumor-stroma interaction in odontogenic tumors may be mediated by Snail.